Table 3.
Univariate analysis for overall survival.
| Characteristic | N (Mean OS *) | 95% CI | p |
|---|---|---|---|
| Sex | 0.400 | ||
| Male | 49 (92) | 79–105 | |
| Female | 39 (82) | 67–97 | |
| Age (years) | 0.103 | ||
| <30 | 28 (80) | 62–98 | |
| ≥30 | 60 (96) | 83–109 | |
| Histological subtype | 0.137 | ||
| NS | 55 (80) | 67–93 | |
| MC | 16 (117) | 102–133 | |
| LR | 8 (86) | 60–111 | |
| NOS | 9 (93) | 66–121 | |
| Ann Arbor stage | 0.132 | ||
| I/II | 38 (87) | 78–96 | |
| III | 10 (86) | 60–112 | |
| IV | 40 (79) | 64–94 | |
| B symptoms at diagnosis | 0.998 | ||
| Present | 53 (89) | 77–101 | |
| Absent | 35 (87) | 72–102 | |
| Bulky disease at diagnosis | 0.009 | ||
| Present | 12 (52) | 37–67 | |
| Absent | 76 (93) | 82–104 | |
| EBV-LMP1 | 0.642 | ||
| Positive | 36 (93) | 78–108 | |
| Negative | 52 (87) | 75–99 | |
| IPS | 0.774 | ||
| 0–2 | 47 (87) | 75–99 | |
| 3–7 | 41 (88) | 73–102 | |
| GHSG | 0.282 | ||
| Limited/Intermediate stages | 23 (74) | 66–83 | |
| Advanced stages | 65 (87) | 75–99 |
* OS in months. NS, Nodular sclerosis; MC, Mixed cellularity; LR, Lymphocyte-rich; NOS, Not otherwise specified; EBV-LMP1, Epstein–Barr Virus Latent Membrane Protein 1; IPS, International Prognostic Score; GSHG, German Hodgkin Study Group. Boldface font indicates statistical significance (p < 0.05).